REDES study: Mepolizumab is effective in patients with severe eosinophilic asthma and comorbid NP
E. Arismendi Nunez (Barcelona, Spain), C. Cisneros (Madrid, Spain), M. Blanco-Aparicio (A Coruña, Spain), D. Bañas Conejero (Madrid, Spain), A. Moure (Madrid, Spain), M. Sánchez-Herrero (Madrid, Spain)
Source: International Congress 2022 – Studies targeting IL-5 pathways in asthma
Session: Studies targeting IL-5 pathways in asthma
Session type: Thematic Poster
Number: 2125
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Arismendi Nunez (Barcelona, Spain), C. Cisneros (Madrid, Spain), M. Blanco-Aparicio (A Coruña, Spain), D. Bañas Conejero (Madrid, Spain), A. Moure (Madrid, Spain), M. Sánchez-Herrero (Madrid, Spain). REDES study: Mepolizumab is effective in patients with severe eosinophilic asthma and comorbid NP. 2125
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|